These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 7911031

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.
    Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, Neal DE.
    Br J Cancer; 1991 Jun; 63(6):967-70. PubMed ID: 1712624
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, Dimopoulos C.
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [Abstract] [Full Text] [Related]

  • 5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M.
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [Abstract] [Full Text] [Related]

  • 6. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ, Aaltomaa S, Syrjänen S, Syrjänen K.
    Anticancer Res; 1993 May; 13(4):1147-52. PubMed ID: 8102517
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group.
    Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P.
    Eur Urol; 1999 Nov; 36(5):393-400. PubMed ID: 10516448
    [Abstract] [Full Text] [Related]

  • 8. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G, Boracchi P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N.
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [Abstract] [Full Text] [Related]

  • 9. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
    Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML.
    Cancer; 1998 Feb 15; 82(4):715-23. PubMed ID: 9477105
    [Abstract] [Full Text] [Related]

  • 10. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW, Ellis IO.
    Br J Cancer; 1992 Sep 15; 66(3):583-8. PubMed ID: 1355662
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
    Akslen LA, Varhaug JE.
    Cancer; 1995 Nov 01; 76(9):1643-54. PubMed ID: 8635070
    [Abstract] [Full Text] [Related]

  • 13. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer.
    Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F.
    Virchows Arch A Pathol Anat Histopathol; 1993 Nov 01; 423(5):329-34. PubMed ID: 7509541
    [Abstract] [Full Text] [Related]

  • 14. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis.
    Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, Ward S, Dykoski D, Harvey J, Niehans GA.
    Am J Clin Pathol; 1994 Feb 01; 101(2):166-76. PubMed ID: 7906919
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.
    Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T.
    Am J Surg; 1992 Oct 01; 164(4):323-6. PubMed ID: 1357997
    [Abstract] [Full Text] [Related]

  • 17. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
    Korkolopoulou P, Konstantinidou AE, Thomas-Tsagli E, Christodoulou P, Kapralos P, Davaris P.
    Appl Immunohistochem Mol Morphol; 2000 Dec 01; 8(4):285-92. PubMed ID: 11127920
    [Abstract] [Full Text] [Related]

  • 18. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.
    Santos LL, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento MJ, Oliveira J, Criado B, Lopes CS.
    Eur J Surg Oncol; 2003 Feb 01; 29(1):74-80. PubMed ID: 12559081
    [Abstract] [Full Text] [Related]

  • 19. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K, Oda Y, Kinukawa N, Naito S, Tsuneyoshi M.
    Hum Pathol; 2005 May 01; 36(5):522-30. PubMed ID: 15948119
    [Abstract] [Full Text] [Related]

  • 20. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE.
    J Natl Cancer Inst; 1993 Jan 06; 85(1):53-9. PubMed ID: 7677935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.